Denosumab: A novel antiresorptive drug for osteoporosis

Ernest Suresh; Bo Abrahamsen

doi:10.3949/ccjm.82a.13173

Denosumab: A novel antiresorptive drug for osteoporosis

Ernest Suresh^*
, Bo Abrahamsen

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Artikel › Forskning › peer review

Abstract

Denosumab is a novel antiresorptive drug that has been approved for use as a first-line drug for primary and secondary prevention of osteoporotic fractures. The authors discuss the mechanism of action of denosumab, review the evidence for its efficacy and safety in patients with osteoporosis, and offer recommendations for its use in clinical practice.

Originalsprog	Engelsk
Sider (fra-til)	105-114
Antal sider	10
Tidsskrift	Cleveland Clinic Journal of Medicine
Vol/bind	82
Udgave nummer	2
DOI	https://doi.org/10.3949/ccjm.82a.13173
Status	Udgivet - 1 jan. 2015
Udgivet eksternt	Ja

Adgang til dokumentet

10.3949/ccjm.82a.13173

Andre filer og links

https://www.scopus.com/pages/publications/84924072215

Citationsformater

@article{aa34d6bbf83f4978a4b150b86a6c03aa,

title = "Denosumab: A novel antiresorptive drug for osteoporosis",

abstract = "Denosumab is a novel antiresorptive drug that has been approved for use as a first-line drug for primary and secondary prevention of osteoporotic fractures. The authors discuss the mechanism of action of denosumab, review the evidence for its efficacy and safety in patients with osteoporosis, and offer recommendations for its use in clinical practice.",

author = "Ernest Suresh and Bo Abrahamsen",

year = "2015",

month = jan,

day = "1",

doi = "10.3949/ccjm.82a.13173",

language = "English",

volume = "82",

pages = "105--114",

journal = "Cleveland Clinic Journal of Medicine",

issn = "0891-1150",

publisher = "Cleveland Clinic Educational Foundation",

number = "2",

}

TY - JOUR

T1 - Denosumab

T2 - A novel antiresorptive drug for osteoporosis

AU - Suresh, Ernest

AU - Abrahamsen, Bo

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Denosumab is a novel antiresorptive drug that has been approved for use as a first-line drug for primary and secondary prevention of osteoporotic fractures. The authors discuss the mechanism of action of denosumab, review the evidence for its efficacy and safety in patients with osteoporosis, and offer recommendations for its use in clinical practice.

AB - Denosumab is a novel antiresorptive drug that has been approved for use as a first-line drug for primary and secondary prevention of osteoporotic fractures. The authors discuss the mechanism of action of denosumab, review the evidence for its efficacy and safety in patients with osteoporosis, and offer recommendations for its use in clinical practice.

UR - https://www.scopus.com/pages/publications/84924072215

U2 - 10.3949/ccjm.82a.13173

DO - 10.3949/ccjm.82a.13173

M3 - Article

C2 - 25897599

AN - SCOPUS:84924072215

SN - 0891-1150

VL - 82

SP - 105

EP - 114

JO - Cleveland Clinic Journal of Medicine

JF - Cleveland Clinic Journal of Medicine

IS - 2

ER -

Denosumab: A novel antiresorptive drug for osteoporosis

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater